Galaxy Medicare FY26 net profit rises to ₹341.81 lakh
Galaxy Medicare Limited reported a net profit of ₹341.81 lakh for the financial year ended March 31, 2026, compared to ₹337.05 lakh in the previous year. Revenue from operations for FY26 stood at ₹4,000.33 lakh, a marginal increase from ₹3,920.16 lakh in FY25. The board approved the audited financial results and recommended a final dividend of ₹0.35 per equity share, subject to shareholder approval. The statutory auditors issued an unmodified opinion but noted an advance payment of ₹50 lakh to the IPO Book Running Lead Manager pending adjustment. The board also approved the re-appointment of key directors, including Mr. Dillip Kumar Das as Managing Director, and re-appointed M/s. Saroj Ray & Associates as Secretarial Auditor.
*this image is generated using AI for illustrative purposes only.
Galaxy Medicare Limited reported a net profit of ₹341.81 lakh for the financial year ended March 31, 2026, compared to ₹337.05 lakh in the previous year. Revenue from operations for FY26 stood at ₹4,000.33 lakh, a marginal increase from ₹3,920.16 lakh in FY25. The board of directors, meeting on May 29, 2026, approved the audited financial results and recommended a final dividend of ₹0.35 per equity share of face value ₹10 each, subject to shareholder approval at the 34th Annual General Meeting.
The statutory auditors, M/s. A. K. Sabat & Co., issued an unmodified opinion on the audited financial results. However, the auditors drew attention to a matter regarding an advance payment of ₹50 lakh made to the Book Running Lead Manager (BRLM) for the IPO before receipt of proceeds, which was not adjusted by the BRLM while recovering fees. The amount is currently treated as "Advance recoverable" under short-term loans and advances.
Financial Performance
The company's total income for FY26 rose to ₹4,131.53 lakh from ₹4,026.82 lakh in the previous year. Total expenditure increased to ₹3,660.85 lakh from ₹3,573.46 lakh. Earnings per share (basic and diluted) for FY26 were reported at ₹2.25, compared to ₹2.84 in the previous year.
| Metric | FY26 (₹ in Lakh) | FY25 (₹ in Lakh) |
|---|---|---|
| Revenue from Operations | 4,000.33 | 3,920.16 |
| Total Income | 4,131.53 | 4,026.82 |
| Total Expenses | 3,660.85 | 3,573.46 |
| Net Profit | 341.81 | 337.05 |
| EPS (Basic) | ₹2.25 | ₹2.84 |
Governance and Appointments
Based on the recommendations of the Nomination & Remuneration Committee, the board approved the re-appointment of Mr. Dillip Kumar Das as Managing Director for a term of two years effective from July 1, 2026, and Mr. Subhasish Das as Whole Time Director for a term of five years effective from August 1, 2026. Additionally, Mr. Shaswat Kumar Rout, Mr. Soumya Mohanty, and Mr. Aklant Das were re-appointed as Independent Directors for a second term of five years effective from April 24, 2026, and September 30, 2026, respectively. All appointments are subject to shareholder approval.
The board also re-appointed M/s. Saroj Ray & Associates, Practicing Company Secretaries, as the Secretarial Auditor for FY27. The company confirmed there were no deviations in the utilization of IPO proceeds during the half-year and year ended March 31, 2026.
Historical Stock Returns for Galaxy Medicare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.28% | 0.0% | +3.95% | +6.47% | -61.50% | -61.50% |
What specific measures will management take to reverse the decline in Earnings Per Share despite the increase in net profit?
What is the expected timeline for recovering the ₹50 lakh advance from the Book Running Lead Manager, and how will this impact cash flow?
How does the company plan to accelerate revenue growth beyond the marginal increase seen in FY26?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
